Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GZBX down on tracking stock decision

Genzyme Biosurgery (GZBX) was down $0.41 (16%) to $2.10 on 2.3 million shares on Friday after Thursday's post-market news that

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE